Arrowhead Pharmaceuticals (ARWR) Non Operating Income (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Non Operating Income of $3.7 million for Q1 2026, up 129.47% on a QoQ basis from -$12.5 million in Q4 2025, and up 131.89% year-over-year from $1.6 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Non Operating Income (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Non Operating Income history runs 17 years deep, the most recent figure standing at $3.7 million for Q1 2026.
- Quarterly Non Operating Income rose 131.89% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.4 million (up 9.94% YoY) and the FY2025 annual result came in at -$46.8 million, down 311.36% from the prior year.
- Non Operating Income was $3.7 million for Q1 2026 at Arrowhead Pharmaceuticals, up from -$12.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.7 million in Q1 2026 and bottomed at -$13.7 million in Q4 2024.
- A 5-year average of -$3.7 million and a median of -$680000.0 in 2023 frame the typical range for Non Operating Income.
- Peak annual rise in Non Operating Income reached 418.24% in 2024, while the deepest fall reached 1505.3% in 2024.
- Arrowhead Pharmaceuticals' Non Operating Income stood at $340000.0 in 2022, then sank by 730.59% to -$2.1 million in 2023, then plunged by 539.13% to -$13.7 million in 2024, then rose by 8.5% to -$12.5 million in 2025, then jumped by 129.47% to $3.7 million in 2026.
- Business Quant data shows ARWR's Non Operating Income at $3.7 million in Q1 2026, -$12.5 million in Q4 2025, and -$8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.14 Bn | 10.36 Bn | - | 3.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.70 Mn |
| Dec 31, 2025 | -12.54 Mn |
| Sep 30, 2025 | -7.99 Mn |
| Jun 30, 2025 | -13.54 Mn |
| Mar 31, 2025 | -11.59 Mn |
| Dec 31, 2024 | -13.70 Mn |
| Sep 30, 2024 | -10.60 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | -805,000.00 |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | -660,000.00 |
| Jun 30, 2023 | -680,000.00 |
| Mar 31, 2023 | -489,000.00 |
| Dec 31, 2022 | 340,000.00 |
| Sep 30, 2022 | 1.67 Mn |
| Jun 30, 2022 | 863,000.00 |
| Mar 31, 2022 | 2.81 Mn |
| Dec 31, 2021 | 1.16 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 1.28 Mn |